ID   LK63 [Melbourne]
AC   CVCL_7986
SY   Lk63; LK-63
DR   BTO; BTO_0000606
DR   Cosmic; 1130240
DR   Cosmic; 2491070
DR   GEO; GSM2373800
DR   GEO; GSM2373801
DR   Wikidata; Q54902673
RX   PubMed=1378917;
RX   PubMed=9067587;
RX   PubMed=27922598;
CC   Doubling time: 13 hours (PubMed=1378917).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Children
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 15
//
RX   PubMed=1378917; DOI=10.1016/0145-2126(92)90016-Z;
RA   Salvaris E., Novotny J.R., Welch K., Campbell L.J., Boyd A.W.;
RT   "Characterization of two novel pre-B-cell lines (LK63 and LiLa-1):
RT   potential models of pre-B-cell differentiation.";
RL   Leuk. Res. 16:655-663(1992).
//
RX   PubMed=9067587; DOI=10.1038/sj.leu.2400571;
RA   Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A.,
RA   Janssen J.W.G., Drexler H.G.;
RT   "Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in
RT   human early B-lineage leukemia cell lines.";
RL   Leukemia 11:441-447(1997).
//
RX   PubMed=27922598; DOI=10.1038/leu.2016.371;
RA   Charmsaz S., Al-Ejeh F., Yeadon T.M., Miller K.J., Smith F.M.,
RA   Stringer B.W., Moore A.S., Lee F.-T., Cooper L.T., Stylianou C.,
RA   Yarranton G.T., Woronicz J., Scott A.M., Lackmann M., Boyd A.W.;
RT   "EphA3 as a target for antibody immunotherapy in acute lymphoblastic
RT   leukemia.";
RL   Leukemia 31:1779-1787(2017).
//